1 brand tagged as Bevacizumab. Discover which parent companies own these brands.
Owned by Roche
Groundbreaking anti-VEGF biologic cancer therapy (bevacizumab) developed by Genentech and owned by Roche, FDA approved February 26, 2004, that reached peak global sales of $7.1 billion in 2019 and now faces biosimilar competition including Mvasi (Amgen) and multiple other approved alternatives.
